• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

治疗性抗体密相的特性和适用性研究及其皮下给药。

Characterization and suitability of therapeutic antibody dense phases for subcutaneous delivery.

机构信息

Center for Molecular and Engineering Thermodynamics, Department of Chemical and Biomolecular Engineering, University of Delaware , Newark, Delaware 19716, United States.

出版信息

Mol Pharm. 2013 Oct 7;10(10):3582-91. doi: 10.1021/mp400006g. Epub 2013 Sep 6.

DOI:10.1021/mp400006g
PMID:24011376
Abstract

Subcutaneous antibody dosing formulations comprising solid suspensions have the potential to reduce dosage viscosity and injection volume. Gel beads of three therapeutic antibodies were prepared to determine the feasibility of such formulations. The beads were formed directly from aqueous solution within 0.1-4 days upon addition of biocompatible precipitating agents under conditions compatible with the use of stabilizing excipients. The phase behavior of antibody gel beads and their mechanical characteristics were measured. Gel beads were characterized by reduced elastic moduli of 0.4-1.0 MPa, as measured by atomic force microscopy, and completely redissolved within 10-20 min under physiologic conditions, in vitro. Crystalline particles could also be prepared in some cases and were found to have reduced elastic moduli 3 orders of magnitude greater than those for the gel beads. Both crystalline and gel particles had protein concentrations of 100-180 mg/mL within the dense phase. Protein stored within the dense phase was recoverable after 40 days of incubation at room temperature or 4 °C.

摘要

包含固体混悬剂的皮下抗体给药制剂有可能降低剂量粘度和注射体积。制备了三种治疗性抗体的凝胶珠,以确定此类制剂的可行性。在添加生物相容性沉淀剂后,在与使用稳定剂赋形剂相容的条件下,这些凝胶珠在 0.1-4 天内直接从水溶液中形成。测量了抗体凝胶珠的相行为及其机械特性。通过原子力显微镜测量,凝胶珠的弹性模量降低到 0.4-1.0 MPa,并且在生理条件下在 10-20 分钟内完全重新溶解,体外。在某些情况下也可以制备结晶颗粒,并且发现它们的弹性模量比凝胶珠低 3 个数量级。结晶颗粒和凝胶颗粒在致密相中都具有 100-180 mg/mL 的蛋白质浓度。在室温或 4°C 下孵育 40 天后,可从致密相中回收储存的蛋白质。

相似文献

1
Characterization and suitability of therapeutic antibody dense phases for subcutaneous delivery.治疗性抗体密相的特性和适用性研究及其皮下给药。
Mol Pharm. 2013 Oct 7;10(10):3582-91. doi: 10.1021/mp400006g. Epub 2013 Sep 6.
2
In vitro release of lysozyme from gelatin microspheres: effect of cross-linking agents and thermoreversible gel as suspending medium.明胶微球中溶菌酶的体外释放:交联剂和热可逆凝胶作为悬浮介质的影响。
Biomacromolecules. 2011 Sep 12;12(9):3186-93. doi: 10.1021/bm200679w. Epub 2011 Aug 11.
3
A Formulation Development Approach to Identify and Select Stable Ultra-High-Concentration Monoclonal Antibody Formulations With Reduced Viscosities.一种制剂开发方法,用于识别和选择具有降低粘度的稳定超高浓度单克隆抗体制剂。
J Pharm Sci. 2017 Nov;106(11):3230-3241. doi: 10.1016/j.xphs.2017.06.017. Epub 2017 Jun 28.
4
Stability of lyophilized sucrose formulations of an IgG1: subvisible particle formation.冻干粉蔗糖制剂的 IgG1:亚可见颗粒形成的稳定性。
Pharm Dev Technol. 2013 Jul-Aug;18(4):883-96. doi: 10.3109/10837450.2012.705295. Epub 2012 Jul 20.
5
Local Crystalline Structure in an Amorphous Protein Dense Phase.无定形蛋白质致密相中的局部晶体结构。
Biophys J. 2015 Oct 20;109(8):1716-23. doi: 10.1016/j.bpj.2015.08.023.
6
Adsorption of monoclonal antibodies to glass microparticles.单克隆抗体对玻璃微球的吸附。
J Pharm Sci. 2011 Jan;100(1):123-32. doi: 10.1002/jps.22275. Epub 2010 Jun 23.
7
Colloidal Instability Fosters Agglomeration of Subvisible Particles Created by Rupture of Gels of a Monoclonal Antibody Formed at Silicone Oil-Water Interfaces.胶体不稳定性促进了由硅油 - 水界面处形成的单克隆抗体凝胶破裂产生的亚可见颗粒的聚集。
J Pharm Sci. 2016 Aug;105(8):2338-48. doi: 10.1016/j.xphs.2016.06.010. Epub 2016 Jul 13.
8
[In vitro evaluation of the gels properties prepared thermosensitive polymers as vehicles for administration substance by injection].[以热敏聚合物为注射给药载体所制备凝胶性质的体外评价]
Polim Med. 2011;41(4):3-15.
9
In vitro and in vivo release of albumin using a biodegradable MPEG-PCL diblock copolymer as an in situ gel-forming carrier.使用可生物降解的MPEG-PCL二嵌段共聚物作为原位凝胶形成载体的白蛋白的体外和体内释放。
Biomacromolecules. 2007 Apr;8(4):1093-100. doi: 10.1021/bm060991u. Epub 2007 Feb 28.
10
In situ gelling xyloglucan/alginate liquid formulation for oral sustained drug delivery to dysphagic patients.原位凝胶化木葡聚糖/海藻酸盐液体配方,用于吞咽困难患者的口服缓释药物递送。
Drug Dev Ind Pharm. 2010 Apr;36(4):449-55. doi: 10.3109/03639040903244480.

引用本文的文献

1
Stability of Protein Pharmaceuticals: Recent Advances.蛋白质类药物的稳定性:最新进展
Pharm Res. 2024 Jul;41(7):1301-1367. doi: 10.1007/s11095-024-03726-x. Epub 2024 Jun 27.
2
Droplet-Based Microfluidic Tool to Quantify Viscosity of Concentrating Protein Solutions.基于液滴的微流控工具用于量化浓缩蛋白质溶液的粘度。
Pharm Res. 2021 Oct;38(10):1765-1775. doi: 10.1007/s11095-021-03106-9. Epub 2021 Oct 18.
3
Stability of a high-concentration monoclonal antibody solution produced by liquid-liquid phase separation.液-液相分离法生产的高浓度单克隆抗体溶液的稳定性。
MAbs. 2021 Jan-Dec;13(1):1940666. doi: 10.1080/19420862.2021.1940666.
4
Optimizing the Bioavailability of Subcutaneously Administered Biotherapeutics Through Mechanochemical Drivers.通过机械化学驱动力优化皮下给予的生物治疗药物的生物利用度。
Pharm Res. 2017 Oct;34(10):2000-2011. doi: 10.1007/s11095-017-2229-9. Epub 2017 Jul 13.
5
Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions.单克隆抗体减粘突变体的合理设计:疏水与静电分子间相互作用
MAbs. 2015;7(1):212-30. doi: 10.4161/19420862.2014.985504.
6
A comparative study of monoclonal antibodies. 1. Phase behavior and protein-protein interactions.单克隆抗体的比较研究。1. 相行为与蛋白质-蛋白质相互作用
Biotechnol Prog. 2015 Jan-Feb;31(1):268-76. doi: 10.1002/btpr.2011. Epub 2014 Nov 19.
7
Concentration dependent viscosity of monoclonal antibody solutions: explaining experimental behavior in terms of molecular properties.单克隆抗体溶液的浓度依赖性粘度:从分子特性角度解释实验行为
Pharm Res. 2014 Nov;31(11):3161-78. doi: 10.1007/s11095-014-1409-0. Epub 2014 Jun 7.